25 assets in Lung Disorder

Therapeutic assets addressing Lung Disorder, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Carboplatin Lung Disorder	Jiangmen Central Hospital	P3	BB (65)
Ivacaftor Lung Disorder	University of British Columbia	P3	BB (64)
Pembrolizumab Lung Disorder	Sarah Goldberg	P3	B (62)
Cis-Diamminedichloroplatinum Ii Lung Disorder	Jiangmen Central Hospital	P3	B (61)
Zimberelimab Lung Disorder	Fundación GECP	P3	B (57)
Adebrelimab Lung Disorder	Jiangmen Central Hospital	P2	CCC (53)
Atezolizumab Lung Disorder	Fundación GECP	P2	CCC (53)
Etoposide Lung Disorder	Pfizer	P2	CCC (53)
Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, Dimer Lung Disorder	Fundación GECP	P2	CCC (53)
pf-08634404 Lung Disorder	Pfizer	P2	CCC (53)
Teniposide Lung Disorder	Shanghai Pulmonary Hospital, Shanghai, China	P2	CCC (53)
Sitravatinib Lung Disorder	Sarah Goldberg	P2	CCC (49)
Primepro™/ Primemsk™ Lung Disorder	Thomas Advanced Medical LLC	P1/2	CCC (48)
Biological Ntla-3001 Lung Disorder	Intellia Therapeutics	P1/2	CC (45)
XENON Lung Disorder	Mario Castro, MD, MPH	P1	CC (43)
Blu-701 Lung Disorder	Blueprint Medicines Corporation	P1	CC (41)
Osimertinib Lung Disorder	Blueprint Medicines Corporation	P1	CC (41)
Pebezertinib Lung Disorder	Blueprint Medicines Corporation	P1	CC (41)
[18f]f-resca-epcd6 Lung Disorder	RenJi Hospital	N/A	D (30)
[18f]f-resca-rt4 Lung Disorder	RenJi Hospital	N/A	D (30)
[18F]F-RESCA-T4 Lung Disorder	RenJi Hospital	N/A	D (30)
[68ga]ga-nota-epcd6 Lung Disorder	RenJi Hospital	N/A	D (30)
[68ga]ga-nota-rt4 Lung Disorder	RenJi Hospital	N/A	D (30)
[68ga]ga-nota-t4 Lung Disorder	RenJi Hospital	N/A	D (30)
Albuterol Lung Disorder	University of British Columbia	N/A	D (30)